Spots Global Cancer Trial Database for Chemoprevention of Oral Premalignant Lesions
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Chemoprevention of Oral Premalignant Lesions
Official Title: Clinical Protocol For A Phase II Double-Blind, Placebo-Controlled, Randomized Study Of Celecoxib (Sc-58635) In Oral Premalignant Lesions, Investigator IND
Study ID: NCT00036283
Conditions
Interventions
Study Description
Brief Summary: Reduction in size and number of oral premalignant lesions
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Pfizer Investigational Site, Farmington, Connecticut, United States
Pfizer Investigational Site, Shreveport, Louisiana, United States
Pfizer Investigational Site, Ann Arbor, Michigan, United States
Pfizer Investigational Site, Minneapolis, Minnesota, United States
Pfizer Investigational Site, New York, New York, United States
Pfizer Investigational Site, Houston, Texas, United States
Pfizer Investigational Site, Seattle, Washington, United States
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
